Skip to main content
Vcanbio Cell & Gene Engineering Corp., Ltd logo

Vcanbio Cell & Gene Engineering Corp., Ltd — Investor Relations & Filings

Ticker · 600645 ISIN · CNE000000545 LEI · 300300FLWFDJPQYVAZ24 Shanghai Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 2,580 across all filing types
Latest filing 2018-08-29 Capital/Financing Update
Country CN China
Listing Shanghai Stock Exchange 600645

About Vcanbio Cell & Gene Engineering Corp., Ltd

https://www.vcanbio.com/

Vcanbio Cell & Gene Engineering Corp., Ltd. specializes in the fields of cell therapy, gene technology, and precision medicine. The company operates a comprehensive business model centered on the storage of hematopoietic and mesenchymal stem cells, providing long-term bio-banking services for cord blood and other biological tissues. Its technical portfolio includes advanced genetic testing services, such as prenatal screening and oncology diagnostics, alongside the development of cell-based therapeutic products. Vcanbio maintains a network of specialized laboratories and storage facilities to support clinical research and personalized healthcare applications. The organization focuses on translating biotechnological advancements into clinical solutions, emphasizing quality control in cell processing and genomic analysis to serve the evolving needs of the regenerative medicine and diagnostic sectors.

Recent filings

Filing Released Lang Actions
东兴证券股份有限公司关于中源协和细胞基因工程股份有限公司发行股份购买资产并募集配套资金暨关联交易实施情况之独立财务顾问核查意见
Capital/Financing Update Classification · 95% confidence The document is titled as an "Independent Financial Advisor's Verification Opinion" regarding a transaction involving issuance of shares to purchase assets and raising supporting funds, including related party transactions. It contains detailed descriptions of the transaction structure, approval processes, asset transfer, capital verification, profit compensation arrangements, and compliance with regulatory approvals, including China Securities Regulatory Commission (CSRC) approval. The document is a comprehensive verification and advisory report by an independent financial advisor on the implementation of a major asset restructuring transaction. It is not a full annual or interim financial report, nor is it a simple announcement or certification. It is a specialized advisory and verification opinion related to a capital/financing transaction and asset acquisition. Therefore, the most appropriate classification is "Capital/Financing Update (CAP)" as it deals with issuance of shares, capital raising, and asset purchase implementation details.
2018-08-29 Chinese
发行股份购买资产并募集配套资金暨关联交易实施情况报告书
Capital/Financing Update Classification · 95% confidence The document is titled as an "Implementation Report" for "Issuance of Shares to Purchase Assets and Raising Supporting Funds and Related Party Transactions" by a listed company on the Shanghai Stock Exchange. It details the transaction parties, the issuance of shares to purchase 100% equity of a target company, the fundraising through non-public issuance of shares, pricing, lock-up arrangements, profit compensation agreements, approvals from regulatory bodies including the China Securities Regulatory Commission (CSRC), and the implementation status of the transaction including asset transfer, capital verification, and registration of new shares. The document includes detailed financial and procedural information about a major asset restructuring transaction, including audit and valuation reports referenced, but it is not a full annual or interim financial report. It is a comprehensive report on the implementation of a major asset acquisition and related fundraising, which fits the category of a Capital/Financing Update (CAP) rather than an Annual Report (10-K), Audit Report (AR), or Regulatory Filing (RNS). The length (15,000 characters) and detailed content confirm it is a full report, not just an announcement. Therefore, the document is best classified as a Capital/Financing Update (CAP).
2018-08-29 Chinese
验资报告
Regulatory Filings
2018-08-29 Chinese
关于转让浙江赛尚医药科技有限公司67%股权的进展公告
Legal Proceedings Report Classification · 95% confidence The document is a public announcement by the company 中源协和细胞基因工程股份有限公司 regarding the progress of the transfer of 67% equity in 浙江赛尚医药科技有限公司. It details the background of the equity transfer agreement, payment delays, breach of contract, and the initiation of legal proceedings. The document is an update on a specific transaction and legal matter, not a full financial report, audit, or earnings release. It does not contain financial statements or detailed financial data. It is not a merger or acquisition announcement but rather a progress update on a capital transaction and related legal action. Therefore, it fits best under Legal Proceedings Report (LTR) as it involves litigation and legal updates related to the equity transfer.
2018-08-27 Chinese
关于发行股份购买资产并募集配套资金暨关联交易之标的资产过户完成的公告
Capital/Financing Update Classification · 95% confidence The document is an official announcement from a company regarding the completion of asset transfer related to a share issuance for asset purchase and fundraising. It details the completion of the asset transfer, registration procedures, and subsequent steps such as share registration and capital changes. It also includes opinions from financial advisors and legal counsel confirming the legality and completion of the transaction. The document is relatively short (2002 characters) and focuses on the announcement of the completion of a significant transaction rather than providing detailed financial statements or comprehensive analysis. This fits the category of a Capital/Financing Update (CAP), which covers updates on company fundraising, financing activities, or capital structure changes.
2018-08-16 Chinese
东兴证券股份有限公司关于中源协和细胞基因工程股份有限公司发行股份购买资产并募集配套资金暨关联交易资产过户事宜之独立财务顾问核查意见
Audit Report / Information Classification · 95% confidence The document is titled as an "Independent Financial Advisor's Verification Opinion" by Dongxing Securities Co., Ltd. regarding Zhongyuan Xiehe Cell Gene Engineering Co., Ltd.'s issuance of shares to purchase assets and raise supporting funds, including related party transactions and asset transfer matters. It references Chinese securities laws, regulations on major asset restructuring, and approval from the China Securities Regulatory Commission (CSRC). The document contains detailed descriptions of the transaction structure, pricing, approval processes, asset transfer completion, and subsequent procedures. It is a formal verification opinion by an independent financial advisor on a major asset restructuring transaction, not a full annual or interim financial report, nor a simple announcement. It is a standalone audit/verification type report related to a major asset restructuring and financing transaction. Therefore, it fits best under the category Audit Report / Information (AR). The document length (9176 characters) and content confirm it is a full report, not just an announcement or certification. Hence, the classification is AR with high confidence. FY 2018
2018-08-16 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.